Disease-modifying therapies for multiple sclerosis: Focus on future direction
November 1st 2012Multiple sclerosis (MS) is a neurologic disorder of chronic inflammation and demyelination of the central nervous system. Several additional agents, including oral products, are now under investigation for the future treatment of MS.
Read More
Discontinuation of warfarin therapy higher than generally anticipated
October 29th 2012Among older adults with atrial fibrillation (AF), persistence with warfarin therapy is generally lower than what has been reported in clinical trials, according study online in Archives of Internal Medicine.
Read More
FDA approves Synribo for chronic myelogenous leukemia
October 26th 2012FDA has approved omacetaxine mepesuccinate (Synribo, Teva) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease. An estimated 5,430 people will be diagnosed with CML in 2012, according to the National Institutes of Health. Synribo is intended to be used in patients whose cancer progressed after treatment with at least 2 drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML.
Read More
ACIP recommends bacterial meningitis vaccine for at-risk infants
October 25th 2012The Advisory Committee for Immunization Practices (ACIP) voted to recommend the use of Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (MenHibrix, GlaxoSmithKline) in infants at increased risk for bacterial meningitis.
Read More
Mass. DPH finds multiple health, safety violations at NECC
October 24th 2012Numerous health and safety violations related to the practice of pharmacy at the New England Compounding Center (NECC), Framingham, Mass. have been documented by investigators of the Massachusetts Department of Public Health (DPH), according to Madeleine Biondolillo, MD, in a press conference Oct. 23
Read More
Investigational drugs to be studied for preventing Alzheimer's
October 23rd 2012Three investigational drugs will be studied in a worldwide clinical trial to determine whether they can prevent Alzheimer’s disease. In people with inherited mutations that cause early-onset Alzheimer’s, the study will seek to identify whether the drugs can improve Alzheimer’s disease biomarkers and prevent the loss of cognitive function.
Read More